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serum protein electrophoresisSystemic amyloidosis is a rare disease that can be rapidly progressive due to widespread organ involve-
ment. There are well-described renal, cardiac, pulmonary, neurological, and dermatologic ﬁndings. Here,
we outline one patient’s experiencewith the condition frompresentation tomaking the diagnosis. She pre-
sented with pathognomonic dermatologic ﬁndings including pinch purpura and ecchymoses found in the
skin folds.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Amyloid is a term selected by the pathologist Rudolf Virchow in 1954
to describe the microscopic depositions he observed as being “cellulose-
like” (Seldin and Skinner, 2012). Amyloidoses are a large group of diseases
in which multifolding of excess proteins renders these proteins insoluble
and results in deposition within organs and tissues (Falk et al., 1997;
Merlini and Bellotti, 2003). Although localized and systemic forms exist,
in the United States less than 10% of cases are the localized form. There
arenoknown racial, occupational, geographic, or environmental predispo-
sitions to this condition (Lachmann and Hawkins, 2012). The incidence of
amyloidosis is unclear, but it is thought to be increasing. From 1950 to
1969, there were 6.1 cases per million, which increased to 10.5 cases per
million between 1970 and 1989 (Lachmann and Hawkins, 2012).
At least 26 unrelated proteins are known to form amyloid ﬁbrils.
While there is a great variety in the precursor protein ﬁbril, diffraction
studies have shown that all amyloid proteins share a similar pattern of
antiparallel β-sheets with a propensity for aggregation (Lachmann and
Hawkins, 2012; Merlini and Bellotti, 2003). In addition to the disease-Inc. on behalf of Women's Der
.speciﬁc protein, all amyloid deposits also contain a proteoglycan,
serum amyloid P, laminin, collagen IV, entactin, and apolipoprotein E
(Kisilevsky, 2000). The misfolded proteins are highly organized, which
is thought to be responsible for the proteins’ stability and resistance to
proteolysis (Lachmann and Hawkins, 2012).
Themost common form of amyloidosis is amyloid light chain (AL am-
yloidosis), in which proteins originate from misfolded monoclonal anti-
body light chains. Plasma cell dyscrasia leads to the overproduction of
these immunoglobulins. In these patients, 5 to 10% of bone marrow cells
are plasma cells (Falk et al., 1997). Not all immunoglobulin light changes
result in amyloidosis; in fact, only 12 to 15% of patients with myeloma
have AL amyloidosis (Falk et al., 1997). However, more than 80% of pa-
tients with clinically signiﬁcant AL amyloidosis have some form of mono-
clonal gammopathy (Lachmann and Hawkins, 2012). These protein
depositions consist of 23-kDa monoclonal Ig light chains or 11-18-kDa
fragments. Although both lambda and kappa subtypes have been de-
scribed, the lambda subtype is most common (Seldin and Skinner, 2012).Case Summary
A 66-year-old woman was referred by her cardiologist to the de-
partment of dermatology with a 2-month history of nonhealing,
inframammary lesions (Fig. 1). These lesions initially presented asmatologic Society. This is an open access article under the CC BY-NC-ND license
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mittently productive of a grey exudate. The lesions were asymptom-
atic with the exception of mild burning when applying nystatin
powder, which failed to produce clinical improvement. The patient
denied pruritus. The patient was in her usual state of good health
until 3 to 4 months before her presentation, when she started to ex-
perienceworsening shortness of breathwith exertion. Shewas found
to have a host of arrhythmic issues such as paroxysmal atrial ﬁbrilla-
tion, atrioventricular nodal reentrant tachycardia (treated with cath-
eter ablation), and sick sinus syndrome. The patient suffered from
severe diastolic heart failure with New York Heart Association class III
symptoms that was increasingly unresponsive to diuretic therapy.
Shewas found to have severe left ventricular hypertrophy on her echo-
cardiogram without any clinical history of hypertension. Her electro-
cardiogram showed slightly diminished voltage in the limb leads.
On exam, the patient had three oval-shaped erosions, two located
in the left inframammary region and one in the right inframammary
region, ranging in size from approximately 2 cm × 1 cm to 4 cm × 3
cm. The bases were bright red and without exudate. Purpura were
present adjacent to the ulcers but were present and more prominent
on the adjoining skin of the breasts. The skin at the inframammary
crease was clear, and no satellite lesions were appreciated (Fig. 1).
The patient was also found to have purpura of the medial half of
the left upper eyelid (Fig. 2). Further questioning revealed a 2-
month history of intermittent eyelid purpura that occurred bilaterally
but with a predilection for the left eyelid.
Laboratories included b-type natriuretic peptide 1457 pg/mL, tro-
ponin I 0.28 ng/mL (Positive 0.05-0.49 ng/mL), Blood Urea Nitrogen
(BUN) 49 mg/dl, creatinine 1.4 mg/dl, and albumin 3.5 g/dl. No
monoclonal protein was detected in the serum; however, serum
immunoﬁxation identiﬁed three precipitin bands, one against
immunoglobulin-G heavy chains and 2 against lambda light chains.
Hemotoxylin and eosin staining of two punch biopsies revealed
amorphous, faintly eosinophilic material in the dermis, which was
suspicious for amyloidosis (Figs. 3 and 4). The diagnosis of amyloid-
osis was conﬁrmed by apple-green birefringence on polarization
and positive staining for Congo red (Figs. 5 and 6).Fig. 1. Ecchymoses and erosions in the inframammary region. Note how the skin at the
inframammary crease is intact whereas skin where friction is likely to be applied is
most affected.The patient has completed a chemotherapy regimen, which
included cyclophosphamide, dexamethasone, and bortezomib to
treat her multiple myeloma and AL amyloidosis. She has had a good
response. Her lambda light chain has decreased from 1099 mg/L to
normal range approximately 5 months after treatment. She still
experiences substantial fatigue and shortness of breathwith exertion.
She continues to have periodic episodes of purpura affecting the
eyelid and the inframammary region but rarely develops erosions.
Discussion
Diagnosis
The diagnosis of amyloidosis is based on clinical suspicion and a
tissue biopsy showing protein deposition. The recommendation is a
punch biopsy of subcutaneous abdominal fat orminor salivary glands
(Desport et al., 2012). Stainingwith Congo red will be positive in 85%
of patients and apple-green birefringence will be exhibited when ex-
posed to polarized light (Falk et al., 1997; Merlini and Bellotti, 2003).
If the biopsy is positive, then the type of amyloidosis should be deter-
mined. AL amyloidosis is the most common type, and a search for
plasma cell dyscrasia should be considered. This workupmay include
serum protein electrophoresis (SPEP) to detect light chains.
SPEP reveals a monoclonal protein expansion in 50% of AL amy-
loidosis patients when serum alone is tested and may show expan-
sion in 86% of patients when serum and urine are tested
simultaneously (Kumar et al., 2013). If the SPEP does not reveal a
spike in light chains and clinical suspicion remains high, one would
then consider immunoﬁxation and a bone-marrow biopsy. If there
is no evidence of plasma-cell expansion, then consideration should
be given to other forms of amyloidosis (Falk et al., 1997). Neverthe-
less, it is not always possible to identify amonoclonal protein, and di-
agnosis of AL amyloidosis is therefore occasionally based on the
clinical presentation (Kumar et al., 2013).
Presentation
AL amyloidosis most frequently affects patients after the age of 50
years old, is rapidly progressive, and can present with widespread
symptoms (Lachmann and Hawkins, 2012). The kidneys are the
most frequently affected organ. Renal involvement presents with
nephrotic-range proteinuria, hypoalbuminemia, secondary hyper-
cholesterolemia, and edema. Occasionally, amyloid is deposited in
the tubules rather than the glomerulus, resulting in azotemiawithout
proteinuria (Seldin and Skinner, 2012).Fig. 2. Waxy ecchymosis on the medial portion of the left upper eyelid. With the
appropriate history, this may represent a pinch purpura classically described as a
waxy, indurated, plaque after minor trauma.
Fig. 3.Hematoxylin and eosin slide from a punch biopsy showing amorphous, eosinophilic material in the dermis. There appears to be increased pigmentation in the basal layer of
the epidermis.
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for 75% of deaths in AL amyloid patients (Desport et al., 2012). Cardiac
involvement, as with our patient, presents as diastolic dysfunctionwith
restrictive cardiomyopathy (Seldin and Skinner, 2012). The characteris-
tic cardiac syndrome includes signs of biventricular congestive heart
failure including peripheral edema, elevated jugular venous pressure,
hepatomegaly, and pulmonary congestion. The disease can also present
with symptoms of low cardiac output, such as fatigue, weakness, and
dizziness (Falk et al., 1997). Systolic function may be preserved until
late in the disease course (Seldin and Skinner, 2012). Cardiac involve-
ment can also include conduction disorders, arrhythmias, or coronary
artery disease (Desport et al., 2012).
The patient’s cardiac and dermatological symptoms began
simultaneously. An estimated 40% of systemic amyloidosis patients
have dermatologic ﬁndings and are more closely associated with
Amyloid Light-Chain (AL) amyloidosis, followed by Transthyretin-
related amyloidosis (ATTR) (familial or transthyretin-related
amyloidosis) and AA (secondary amyloidosis) (Campbell et al.,
2011). The majority of skin ﬁndings are thought to be caused by
hemorrhage secondary to amyloid protein inﬁltration of blood vesselFig. 4. Close up of the previous slide showing amorphous deposition of eosinophilicwalls. Thus, we often see the stigmata of vascular involvement, in-
cluding petechiae, purpura, and ecchymoses (Kumar et al., 2013).
These hemorrhagic skin ﬁndings are called amyloid purpura
(Colucci et al., 2014) or pinch purpura (Kisilevsky, 2000) and can
present as waxy indurations anywhere on the body after even
minor trauma (Falk et al., 1997). Flexural regions aremost commonly
involved, including theeyelids and inframammary regions (Kumar et al.,
2013). Bilateral periorbital ecchymoses, or raccoon eyes, are almost
pathognomonic for amyloidosis, although the differential diagnosis also
includes basilar skull fracture and neuroblastoma (Colucci et al., 2014).
Other less common dermatologic manifestations of systemic am-
yloidosis have been described, including nonhealing ulcers, bullae,
macroglossia, nodules, plaques, papules, telangiectasias, hyperpig-
mentation, inﬁltrate similar to scleroderma, alopecia, nail dystro-
phies, cutis laxa, and even a blue skin tint (Campbell et al., 2011;
Chandran et al., 2011; Kumar et al., 2013).
In addition to hemorrhagic skin lesions, more severe skin or
internal bleeding can occur due to coagulation factor inhibitory circu-
lating paraprotein, hyperﬁbrinolysis, platelet dysfunction, or isolated
acquired factor X deﬁciency (Colucci et al., 2014).material. Classically, these depositions are found within the papillary dermis.
Fig. 5. Congo-red stain highlighting the deposition of amyloid protein.
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neuropathy and/or autonomic dysfunction. Patients may complain
of dysthesias, postural hypotension, impotence, and disruption of
gastrointestinalmotility (Merlini andBellotti, 2003). Rarely, gastroin-
testinal symptoms manifest as malabsorption or pseudo-obstruction
(Merlini and Bellotti, 2003). Hepatic and splenic involvementmay in-
clude organomegaly and decreased functionality. Macroglossia with
indentations on the tongue or an immobile tongue is pathognomonic
for AL amyloidosis and affects 10 to 20% of patients (Merlini and
Bellotti, 2003; Seldin and Skinner, 2012). Enlargement of the tongue
can create pressure against the teeth, leaving indentations in the
tongue. Amyloid deposition into soft tissue can include synovial dis-
position leading to the shoulder pad sign (Merlini and Bellotti,
2003), nail dystrophies, and alopecia (Merlini and Bellotti, 2003;
Seldin and Skinner, 2012).Treatment
The treatment of AL amyloidosis includes chemotherapy to treat
the underlying cause of amyloid protein production and supportive
care for affected organ systems.Fig. 6. Congo-red stained slide under polarization demonstratingSummary
Amyloidosis should be considered in patients with dermatologic
ﬁndings including purpura,macroglossia, and/or periorbital ecchymoses,
especially in the setting of concurrent unexplained cardiomyopathy, ne-
phropathy, and/or neuropathy. Although macroglossia and periorbital
ecchymoses are speciﬁc for amyloidosis, they occur in the minority of
amyloidosis patients. Theprognosis of amyloidosis remainspoor, andde-
termining and treating the underlying cause is the cornerstone of treat-
ment (Lachmann and Hawkins, 2012). Minimizing morbidity and
mortality in amyloidosis patients requires maintaining a high degree of
suspicion to allow for the earliest possible diagnosis.Acknowledgements
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